Last reviewed · How we verify
Investigational COVID-19 Vaccine 2
Investigational COVID-19 Vaccine 2 is a Biologic drug developed by ModernaTX, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational COVID-19 Vaccine 2 |
|---|---|
| Sponsor | ModernaTX, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Fatigue
- Injection site pain
- Myalgia
- Chills
- Arthralgia
- Injection site pain (PAIN)
- Pyrexia
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Nausea
- Chills (CHILLS)
Key clinical trials
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People (PHASE1, PHASE2)
- Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above (PHASE1)
- Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People (PHASE1)
- A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults (PHASE1, PHASE2)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza. (PHASE3)
- A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults (PHASE2)
- A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational COVID-19 Vaccine 2 CI brief — competitive landscape report
- Investigational COVID-19 Vaccine 2 updates RSS · CI watch RSS
- ModernaTX, Inc. portfolio CI
Frequently asked questions about Investigational COVID-19 Vaccine 2
What is Investigational COVID-19 Vaccine 2?
Investigational COVID-19 Vaccine 2 is a Biologic drug developed by ModernaTX, Inc..
Who makes Investigational COVID-19 Vaccine 2?
Investigational COVID-19 Vaccine 2 is developed by ModernaTX, Inc. (see full ModernaTX, Inc. pipeline at /company/modernatx-inc).
What development phase is Investigational COVID-19 Vaccine 2 in?
Investigational COVID-19 Vaccine 2 is in Phase 1.
What are the side effects of Investigational COVID-19 Vaccine 2?
Common side effects of Investigational COVID-19 Vaccine 2 include Headache, Fatigue, Injection site pain, Myalgia, Chills, Arthralgia.